ProPhase Labs, Inc. · OTC:PRPH
ProPhase Labs — Investor Presentation (April 2023)
42 slides from ProPhase Labs's investor presentation, Apr 25, 2023
Slide 1: April 2023 Investor Presentation
ProPhase —__ - April 2023 Investor Presentation q Be ProPhaseLabs.com 9 NASDAQ: PRPH N \a
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements relating to our strategy and business objectives. All statements other than statements of historical facts included in this presentation may be deemed to be forward-looking statements including statements regarding our
Slide 3: Ted Karkus, Chairman & CEO: Our best is yet to come
TED KARKUS, CHAIRMAN & CEO Our best is yet to come. “We believe we are destined to become a multibillion company. Our focused execution and smart diversification strategy have. delivered stellar financial results, while the acquisition, licensing, and development of cutting-edge assets have billion-
Slide 4: The Five Divisions of ProPhase Labs
THE FIVE DIVISIONS OF PROPHASE LABS Nebut © Cenonios _gProPhase 04
Slide 5: Performance Track Record
PERFORMANCE TRACK RECORD Beginning in au 2018 2021 Q4 2020 Turnaround Big Sale Special Commenced Commenced Dividends CLIA Lab Genetic Services Sequencing eteeueeza, aera ererey Longterm shareholders Expanded into Covid-19 Acquisition of Nebula Ee on arias wellrewarded.as Company _‘estingandwithina s
Slide 6: Performance Track Record Continued
PERFORMANCE TRACK RECORD CONTINUED Q4 2021 Q2 2022 Q3 2022 Q4 2022 Q12023 Reported FY 2021 Results Strong Revand Earnings growth for FY2021 - Reported Net Rev of $79m vs, $14.5m for FY2020. FY2021 Net Income - $6.3m vs. net loss of $2.1m FY 2020, FY2021 Adj EBITDA $$18.1m vs, ($307,000) FY2020. 1. S
Slide 7: Nebula Genomics
Nebul: Ww Genome April 2023 Nebula Genomics
Slide 8: Right to Win - Personal Genome Sequencing
RIGHT TO WIN - PERSONAL GENOME SEQUENCING Nebut & Csnomics Mission: To usher in the era of personal genomics by providing eve enon a oes access to affordable and secure Whole Genome Sequencing. available around the globe. Prof. George Church, co-founder of Nebula Genomics; Professor of Genetics at H
Slide 9: Leaders in Whole Genome Sequencing (WGS)
LEADERS IN WHOLE GENOME SEQUENCING (WGS) WGS - genetic sequencing technology obtains comprehensive data on every gene and chromosomes in DNA. Can be used to examine ancestry, health, diet, rare gene mutations and potential predisposition to disease. Provides the consumer and business access to affor
Slide 10: Right to Win - Best Insights + Tools
RIGHT TO WIN - BEST INSIGHTS + TOOLS published genetic sos as A studies, with new Intesthnes Cancer = research every week sor ame BUT ne 41. They are hard to understand for the most. 2. And are locked behind paywalls. The Nebula Library keeps you informed about the latest genomic discoveries to help
Slide 11: Nebula's Omni-Channel Growth Strategy
NEBULA'S OMNI-CHANNEL GROWTH STRATEGY UY BE orcs Collaboration with G42 Healthcare: Oct 2022, announced MOU with Nebula Genomics. G42 is a leading, Abu Dhabi-based artificial intelligence (Al) health- tech company. + Explore several collaborative opportunities: genomic sequencing, artificial intelli
Slide 12: Diagnostics
DIAGNOSTICS April 2023 _ ProPhase _ Diagnostics
Slide 13: ProPhase Diagnostics
PROPHASE DIAGNOSTICS Focused on providing a fully integrated diagnostic laboratory services with a complete clinical lab offering. Operates two state-of-the-art, Clinical Laboratory Improvement Amendments (CLIA) accredited laboratories, New York (recently expanded to 30,000 sq, ft.) and New Jersey.
Slide 14: Esophageal Adenocarcinoma - One of the Deadliest Cancers
ESOPHAGEAL ADENOCARCINOMA - ONE OF THE DEADLIEST CANCERS Gastroesophageal Reflux Disease (GERD) occurs when stomach acid repeatedly flows back into the esophagus. This backwash (acid reflux) can irritate the lining of your esophagus. Many experience acid reflux from time to time; for some, GERD may
Slide 15: Esophageal Cancer - One of the Deadliest and Most Common Cancers
ESOPHAGEAL CANCER - ONE OF THE DEADLIEST AND MOST COMMON CANCERS 16,000+ Estimated Deaths in 2022! in the US. 79.4% - 5-Year Mortality Rate 20,000+ - Estimated New Cases in 2022! The change in the annual idence of EAC compared to 1973 6th leading cause of cancer related deaths; 8th most common cer w
Slide 16: BEsmart - Esophageal Pre-Cancer Diagnostic
BEsmart™ - ESOPHAGEAL PRE-CANCER DIAGNOSTIC Initially developed by Dr. Christopher Hartley (Mayo Clinic), Dr. Joe Abdo. (Georgetown University), Dr. Devendra Agarwal (Western University), Dr. Sumeet K. Mittal (Norton Thoracic Institute- St Joseph Hospital ) as an early detection to identify and quan
Slide 17: BEsmart - Tech + Goals
BEsmart™ - TECH + GOALS 1 PREDICTION Proteomic expression panel that can predict Barrett’s progressing into cancer (patent pending) 2 OPTIMIZATION Proteomic panel for Esophageal Adenocarcinoma (EAC) to predict therapeutic efficacy of chemo and targeted therapy 3 PREVENTION Proteomic panels to predic
Slide 18: Esophageal Cancer - Opportunity
ESOPHAGEAL CANCER - OPPORTUNITY Prevalence of GERD in the U.S ranges from 18.1% to 27.8% in North America (Census 303 million)" ~ 60 million Prevalence of Barrett's Esophagus in the US. is 5.6% of the population (Census 303 million) * New Cases of Esophageal Adenocarcinoma in US. per year* Endoscopy
Slide 19: BEsmart - Near Term Path to Commercialization
BEsmart™ NEAR TERM PATH TO COMMERCIALIZATION 2021-2022 1H 2023 2H 2023 1H 2024 <7] Filed US Patent May 19, 2021 5 Initiated 1000 patient on STLA101 Assay with the Mayo Clinic, Zi Completed first -200 tests. ‘£1 Submitted and Presented interim Study Results to ACG/ASCO-GI/SAGES/AACR/DDW 2022 2] Filed
Slide 20: ProPhase BioPharma
ProPhase Qa ScPikeon April 2023 ProPhase BioPharma
Slide 21: ProPhase BioPharma (PBIO) - Novel Drugs + Biotech Compounds
PROPHASE BIOPHARMA (PBIO) - NOVEL DRUGS + BIOTECH COMPOUNDS Acquired exclusive, worldwide development and commercialization rights that were developed by Global Research and Discovery Group (GRDG) - scientific think tank and research organization working with: BARDA (Biomedical Advance Research Deve
Slide 22: Equivir Portfolio - Novel Polyphenols Blends
EQUIVIR™ PORTFOLIO- NOVEL POLYPHENOLS BLENDS FOR MEDS + SUPPLEMENTS Equivir portfolio is designed to supplement the body and work by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells. Blend of Polyphenols Myricetin Hesperidin Piperine PBIO
Slide 23: LB-1 Co-Therapy with Doxorubicin
LB-1 CO-THERAPY WITH DOXORUBICIN LB-1 Activity investigated as Co-therapy with Doxorubicin in cell line proliferation in-vitro study LB] and Downdicin conbined eff. an'F47D prolration Linebacker-1+Doxorubicin-Relatively Cell inhibition of vehicle control(%) Dox (nM) we 11 concentation(.M) 00 50% #20
Slide 24: Linebacker - Pre-Clinical Development
LINEBACKER™ PRE-CLINICAL DEVELOPMENT Announced two-year collaboration with Dana-Farber/Harvard to develop LB-1 as a cancer co-therapy. Intended as a therapy enhancer for traditional chemotherapeutic agents to both increase efficacy and decrease toxicity in current cancer treatments. Provides year 1
Slide 25: Manufacturing, Inc.
Manufacturing, Inc. » Pharmaloz C © Manufacturing cae = TK Supplements
Slide 26: Pharmaloz Manufacturing - 3X Capacity Anticipated in 2024
PHARMALOZ MANUFACTURING - 3X CAPACITY ANTICIPATED IN 2024 One of the Largest, State-of-the-Art Lozenge Manufacturers in the US. Contract Manufacturing: 60,000 sq, ft. climate-controlled facility on 12 acres operating under FDA 21 CFR 210 & 211 guidelines provides the ability to offer products for di
Slide 27: TK Supplements
TK SUPPLEMENTS® alline of dietary supplements dedicated to providing clinically tested products for men's sexual health, wet LEGENDZ XL® ‘or male sexual enhancement. Event based; clinically proven to promote blood flow in < 60min with frst se. TRIPLE EDGE XL® 2 dally energy and stamina booster Daily
Slide 28: Growth Strategy
ProPhase RBS Growth Strategy ProPhaseLabs.com NASDAQ: PRPH
Slide 29: BioPharma Product Pipeline
BIOPHARMA PRODUCT PIPELINE BEsmart™ Linebacker™ Esophageal Targeted Therapeutic Platforms _ ProPhase Validation Equivir Dietary supplement to help maintain proper Immune function, Multi-ci to strengthen clain 2023, BE-Smart Break-through e screening test. of contracting ‘esophageal can save countles
Slide 30: Growth & Expansion in the MENA Region
GROWTH & EXPANSION IN THE MENA REGION Nebula Genomics ct 2022, announced collaboration through an MOU with Nebula Genomics and G42 Healthcare - a leading, Abu Dhabi- based artificial intelligence (Al) health-tech company. Collaborative opportunities: genomic sequencing Al, sharing of genomic data in
Slide 31: Financial Highlights
rs ProPhase ——__ = u Financial Highlights ProPhaseLabs.com NASDAQ: PRPH
Slide 32: Company Snapshot
COMPANY SNAPSHOT Socragmtial PRPH ProPhase Labs is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry- Exchange [[NASbat leading Whole Genome Sequencing solutio
Slide 33: Strong Three Year Growth & Financial Performance
STRONG THREE YEAR GROWTH & FINANCIAL PERFORMANCE 5 5% et Reiantis Forte Fees Perea ercive(corerey ‘° 2022- $122.6m INCREASE ——2021-$79.0m 300% Net Income - © 2022-s18.5m INCREASE 2021-$6.3m , 200% ssss12000»- he © 2022-8386m ori INCREASE = 2021-$17.1m As of Dec 31, 2022 Cash, cash equivalents and ma
Slide 34: A History of Dividend Returns to Investors
A HISTORY OF DIVIDEND RETURNS TO INVESTORS Dat 6/3/2022 3/10/2022 6/3/2021 12/12/2019 4124/2019 6/5/2018 —_— $2.70/share in Special Dividends in ~ 5 years Summary Caj Basic Shares Outstanding 17.2m Options (WAEP: USD $5.35)" 2.8m Warrants (WAEP: USD $8.23)' 0.9m Fully Diluted Shares Outstanding’ 18.
Slide 35: Peer Group Analysis
PIER GROUP ANALYSIS: GENO MICS Enterprise Value/ ITM Revenue LOPS AES Sf foe Eee PRPH 1.0x vs. © 4.2x Pier Group Average PISCOUNT bier Group Mean/Median LTM EBITDA Margin: (53.8%)/(50.6%) compared to PRPH 23.1%. ProPh aS eed As of April 20, 2023 35
Slide 36: Management & Board of Directors
ProPhase Management & Board of Directors ProPhaseLabs.com NASDAQ: PRPH
Slide 37: Executive Management
EXECUTIVE MANAGEMENT Ted Karkus Chairman & CEO Ted Karkus, CEO and Chairman of ProPhase Labs, drives the company's diverse and synergistic businesses with his successful track record in biomedical and health companies. He transformed ID Biomedical’ strategy and valuation from $25 milion to $1.4 bill
Slide 38: Executive Management
EXECUTIVE MANAGEMENT & *@ Robert A Morse JasonKarkus Alice Lioi CFO. President EVP/COO - ProPhase ProPhase Diagnostics, Diagnostics, Inc. Inc. ProPhase BioPharma, Inc. Robert joined ProPhase Labs Jason drove explosive revenue As head of alla operations, a5 Coeporate Controle, ‘routh a ProPhase ‘lice
Slide 39: Board of Directors and Nebula Advisory Board
BOARD OF DIRECTORS AND NEBULA ADVISORY BOARD Jason Barr Director Jason M, Barr has been a member of ur Board since june 2015, He is currently the General Counsel and Secretary of thaca Holdings, LC. a music abe, artist management and entertainment company based in Los Angles. He previously was the D
Slide 40: ProPhase Labs Contact
6 ProPhase LABS ProPhaseLabs.com, TED KARKUS Chairman & CEO 71 Stewart Ave., Suite 200 Garden City, NY 11530 INSTITUTIONAL INVESTOR RELATIONS 267-880-1111 RETAIL INVESTOR RELATIONS John Boidman. Renmark Financial Communications 514-939-3989
Slide 41: Appendix
rn ProPhase _ APPENDIX ProPhaseLabs.com NASDAQ: PRPH
Slide 42: Appendix A: GAAP to Non-GAAP Reconciliation
APPENDIX A GAAP to Non-GAAP Reconciliation We define EBITDA as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, bother non-cash items, and other unusual or non-recurring charges (as desc